{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-014643","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.633457+00:00","generated_at":"2026-06-06T03:06:39.297083+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MEI Pharma reports Q2 FY2024 results; cash $59.5M, zero revenue, clinical data readouts expected H1 2024","bullets":["Cash, cash equivalents and short-term investments of $59.5M at Dec 31, 2023, with no outstanding debt.","Revenue zero for Q2 ended Dec 31, 2023 vs $32.7M prior year due to Kyowa Kirin agreement termination.","R&D expenses fell to $3.9M in Q2 from $15.3M Q2 prior year, driven by zandelisib program wind-down.","Expects initial safety/efficacy data for voruciclib (CDK9 inhibitor) and ME-344 (mitochondrial inhibitor) in first half of 2024.","Cash used in operations was $29.5M for six months ended Dec 31, 2023, comparable to $29.1M prior period."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-014643","json":"https://secwatch.observer/filing/0000950170-24-014643.json","markdown":"https://secwatch.observer/filing/0000950170-24-014643.md","text":"https://secwatch.observer/filing/0000950170-24-014643.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/0000950170-24-014643-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/meip-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:06:39.297083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbfffd7a8e889da344bfeecfa3c74bcd14f87f1d","claim":"Lite Strategy, Inc. reported financial results for second quarter ended December 31, 2023.","evidence_excerpt":"On February 13, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024014643/0000950170-24-014643-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}